{"id":10356,"date":"2022-09-27T05:47:23","date_gmt":"2022-09-27T05:47:23","guid":{"rendered":"https:\/\/marylanddailygazette.com\/major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\/"},"modified":"2022-09-27T05:47:23","modified_gmt":"2022-09-27T05:47:23","slug":"major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\/","title":{"rendered":"Major Depressive Disorder Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\">Major Depressive Disorder Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight<\/a><\/p>\n<p><div><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/LppGKl.png\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Major Depressive Disorder Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/LppGKl.png\" alt=\"Major Depressive Disorder Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight\" width=\"225\"><\/a><\/div>\n<p><strong><em>\u201cDelveInsight\u2019s, Major Depressive Disorder Pipeline Insight 2022 report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape\u201d<\/em><\/strong><\/p>\n<p>It covers the Major Depressive Disorderpipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disordertherapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p><strong>Key takeaways from the Major Depressive Disorder Pipeline Report<\/strong><\/p>\n<ul>\n<li>DelveInsight\u2019s <strong>Major Depressive Disorder Pipeline <\/strong>analysis depicts the space with 75+ active players working to develop 75+ pipeline therapies.<\/li>\n<li>The <strong>Major Depressive Disorder <\/strong>pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.<\/li>\n<li>Major Depressive Disorder Pipeline companies included <strong><em>GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research &amp; Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals,<\/em><\/strong> and many others<\/li>\n<li>Major Depressive Disorder Pipeline Therapies included <strong><em>SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421<\/em><\/strong>, and many others.<\/li>\n<\/ul>\n<p><strong>To know more about the Major Depressive Disorder Pipeline report, click here:-&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight<\/a><\/strong><\/p>\n<p><strong>Major Depressive Disorder Overview<\/strong><\/p>\n<p>Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn\u2019t known. However, there are several factors that can increase the risk of developing the condition. Symptoms must occur for a period of 2 or more weeks and at least one symptom is either depressed mood or loss of interest or pleasure. MDD is often treated with medication and psychotherapy. Some lifestyle adjustments can also help ease certain symptoms.<\/p>\n<p>The Gastrointestinal Stromal Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p><strong>Major Depressive Disorder Pipeline Insight Report<\/strong><\/p>\n<p>Major Depressive Disorder Pipeline Insight, 2022\u2033 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of Wilson\u2019s disease pipeline landscape is provided which includes the disease overview and Major Depressive Disorder treatment guidelines.<\/p>\n<p><strong>DelveInsight\u2019s Major Depressive Disorder Pipeline report covers around 75+ products under different phases of clinical development like-<\/strong><\/p>\n<ul>\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of&nbsp;<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p><strong>Emerging Major Depressive Disorder Drugs under Different Phases of Clinical Development Include:-<\/strong><\/p>\n<ul>\n<li>SAGE-217: Sage Therapeutics<\/li>\n<li>REL-1017: Relmada Therapeutics, Inc<\/li>\n<li>Seltorexant: Minerva Sciences<\/li>\n<li>SP-624: Sirtsei Pharmaceuticals, Inc.<\/li>\n<li>SPL026: Small Pharma<\/li>\n<li>PDC-1421: BioLite Inc<\/li>\n<\/ul>\n<p><strong>Download the Major Depressive Disorder Pipeline Report to learn more about the emerging Major Depressive Disorder emerging therapies at @ <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-pipeline-insight <\/a><\/strong><\/p>\n<p><strong>Major Depressive Disorder Pipeline Therapeutic Analysis<\/strong><\/p>\n<p>There are approx. 75+ key companies which are developing therapies for Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.<\/p>\n<p><strong>Major Depressive Disorder Pipeline&nbsp;development activities<\/strong><\/p>\n<p>The Major Depressive Disorder pipeline report provides insights into:<\/p>\n<ul>\n<li>All of the companies that are developing therapies for the treatment of&nbsp;Major Depressive Disorder with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;Major Depressive Disorder<\/li>\n<li>Major Depressive Disorder key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;Major Depressive Disorder<\/li>\n<\/ul>\n<p>The&nbsp;<strong>Major Depressive Disorder <\/strong>Pipeline Report is built using data and information traced from the researcher\u2019s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p><strong>Request for Sample PDF Report to know more about Major Depressive Disorder drugs and therapies \u2013&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight&nbsp;<\/a><\/strong><\/p>\n<p><strong>Table of Content<\/strong><\/p>\n<ol start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Major Depressive Disorder: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Major Depressive Disorder \u2013 DelveInsight\u2019s Analytical Perspective<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<li>SAGE-217: Sage Therapeutics<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>SP-624: Sirtsei Pharmaceuticals, Inc.<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>SPL026: Small Pharma<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>Drug Name: Company name<\/li>\n<li>Inactive Products<\/li>\n<li>Major Depressive Disorder Key Companies<\/li>\n<li>Major Depressive Disorder Key Products<\/li>\n<li>Major Depressive Disorder- Unmet Needs<\/li>\n<li>Major Depressive Disorder- Market Drivers and Barriers<\/li>\n<li>Major Depressive Disorder- Future Perspectives and Conclusion<\/li>\n<li>Major Depressive Disorder Analyst Views<\/li>\n<li>Major Depressive Disorder Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p><strong>Download Sample PDF Report for Major Depressive Disorder clinical trials advancements @&nbsp;<a href=\"https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/major-depressive-disorder-pipeline-insight<\/a><\/strong><\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=major-depressive-disorder-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies-by-delveinsight\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Mon, 26 Sep 2022 21:18:08 -0500<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Major Depressive Disorder Pipeline Assessment \u2013 FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies by DelveInsight \u201cDelveInsight\u2019s, Major Depressive Disorder Pipeline Insight 2022 report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape\u201d It covers the Major Depressive Disorderpipeline drug [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10355,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10356"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=10356"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/10355"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=10356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=10356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=10356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}